About this item:

73 Views | 25 Downloads

Author Notes:

anessa Rouzier, Pediatrics, GHESKIO Centers, Port-au-Prince, Haiti. email: vrouzier@gheskio.org

The authors thank the study participants and their families; and the site investigators, study teams and protocol team of A5300/I2003.

University of Cape Town Lung Institute, Cape Town, South Africa (Site 31792; Grant 110205); Barranco Clinical Research Site (CRS), Lima (Site 11301; Grant 5UM1AI069438-10); San Miguel CRS, Lima, Peru (Site 11302; Grant 110199); Byramjee Jeejeebhoy Government Medical College CRS, Pune (Site 31441; Grant UM1AI069465); Chennai Antiviral Research and Treatment (CART) CRS, Chennai, India (Site 11701; Grant UM01 A1069432); TASK CRS, Cape Town, South Africa (Site 31718; Grant UM1AI069521); Wits Helen Joseph Hospital CRS, Johannesburg (Site 11101; Grant AI069463); South African Tuberculosis Vaccine Initiative (SATVI), Cape Town, South Africa (Site 31793; Grant 5UM1AI068636-10); GHESKIO Centers IMIS, Port-au-Prince, Haiti (Site 31730; Grant 5UM1AI069421); Desmond Tutu TB Centre, Stellenbosch University, Tygerberg, South Africa (Site 31790); Gaborone CRS, Botswana (Site 12701; Grant UM1AI069456); Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand (Site 5116; Grant HHSN275201300003C); Soweto AIDS Clinical Trials Group CRS, Johannesburg (Site 12301; Grant 5UM1AI069453); Durban International CRS, Enhancing Care Foundation, Durban, South Africa (Site 11201; Grant 2UM1AI069432-08); Instituto Nacional de Infectologia, INI/Fiocruz, Rio de Janeiro, RJ, Brazil (Site 12101; Grant 5UM1AI069476-09); Kisumu CRS, Kisumu, Kenya (Site 31460) Emory-Centers for Disease Control and Prevention HIV/AIDS Clinical Trials Unit, Atlanta, GA, USA (Grant UM1AI069418)

Subject:

Research Funding:

This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH; Bethesda, MD, USA) [UM1AI068634, UM1AI068636, and UM1AI106701 to AIDS Clinical Trials Group]. Overall support for IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network) was provided by the NIAID, with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH) of NIH [UM1AI068632, UM1AI068616, UM1AI106716], and by NICHD contract number [HHSN275201800001I]. MTM received training support from the Johns Hopkins University Medical Scientist Training Program (Baltimore, MD, USA) funded by the National Institute of General Medical Sciences [5T32GM007309-43] as well as the UJMT Fogarty Global Health Fellowship [D43TW009340] funded by the Fogarty International Center; National Institute of Neurological Disorders and Stroke; National Heart, Lung and Blood Institute; and National Institute Environmental Health Sciences of the NIH. AG was supported by NIH/NIAID UM1 AI069465.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Infectious Diseases
  • Respiratory System
  • tuberculosis
  • contacts
  • pediatric
  • children
  • prophylaxis
  • MULTIDRUG-RESISTANT
  • LATENT TUBERCULOSIS
  • PREVENTIVE THERAPY
  • YOUNG-CHILDREN
  • CONTACTS
  • MANAGEMENT
  • HOUSEHOLDS
  • KNOWLEDGE
  • ADULT

Caregiver willingness to give TPT to children living with drug- resistant TB patients

Show all authors Show less authors

Tools:

Journal Title:

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Volume:

Volume 26, Number 10

Publisher:

, Pages 949-955

Type of Work:

Article | Final Publisher PDF

Abstract:

BACKGROUND: Pediatric household contacts (HHCs) of patients with multidrug-resistant TB (MDR-TB) are at high risk of infection and active disease. Evidence of caregiver willingness to give MDR-TB preventive therapy (TPT) to children is limited. METHODS : This was a cross-sectional study of HHCs of patients with MDR-TB to assess caregiver willingness to give TPT to children aged ,13 years. RESULT S : Of 743 adult and adolescent HHCs, 299 reported caring for children aged ,13 years of age. The median caregiver age was 35 years (IQR 27-48); 75% were women. Among caregivers, 89% were willing to give children MDR TPT. In unadjusted analyses, increased willingness was associated with TB-related knowledge (OR 5.1, 95% CI 2.3-11.3), belief that one can die of MDR-TB (OR 5.2, 95% CI 1.2-23.4), concern for MDR-TB transmission to child (OR 4.5, 95% CI 1.6-12.4), confidence in properly taking TPT (OR 4.5, 95% CI 1.6-12.6), comfort telling family about TPT (OR 5.5, 95% CI 2.1-14.3), and willingness to take TPT oneself (OR 35.1, 95% CI 11.0-112.8). CONCLUS IONS : A high percentage of caregivers living with MDR- or rifampicin-resistant TB patients were willing to give children a hypothetical MDRTPT. These results provide important evidence for the potential uptake of effective MDR TPT when implemented.

Copyright information:

© 2022 The Union

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote